Floatz logo

Duoc-01

Primary Progressive Multiple Sclerosis

Joanne Kurtzberg, MDCell therapyPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the Primary Progressive Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Ocrelizumab
Indapta Therapeutics, INC.
Phase 4BBB
Fampridine
University College Dublin
Phase 4BBB
Rituximab
Rigshospitalet, Denmark
Phase 3B
Diphenhydramine
Hoffmann-La Roche
Phase 3B
Tolebrutinib
Sanofi
Phase 3B

View all 45 →

Same molecule, other indications

Duoc-01 is also rated in:

juvenile neuronal ceroid lipofuscinosisActive
CC
Indicative · Phase 1
43 / 100
View asset →
mucopolysaccharidosis type 2Active
CC
Indicative · Phase 1
43 / 100
View asset →
adrenoleukodystrophyActive
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →